Acute Lymphoblastic Leukemia ⎼ Posters and Abstracts from San Diego

Slides:



Advertisements
Similar presentations
Oncologic Drugs Advisory Committee
Advertisements

Brown JR et al. Proc ASH 2013;Abstract 523.
LaCasce A et al. Proc ASH 2014;Abstract 293.
Roberts AW et al. Proc ASH 2014;Abstract 325.
Safe and Effective Re-Induction of Complete Remissions in Adults with Relapsed B-ALL Using 19-28z CAR CD19-Targeted T Cell Therapy Davila ML et al. Proc.
Arsenic Trioxide (ATO) in the Consolidation Treatment of Newly Diagnosed APL — First Interim Analysis of a Randomized Trial (APL 2006) by the French Belgian.
Viardot A et al. Proc ASH 2014;Abstract 4460.
A Phase II Study with Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma Bringhen S et al. Proc ASH 2013;Abstract.
Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin plus Cytarabine versus Placebo plus.
Long-term Outcome after hyper-CVAD and Imatinib for De Novo or Minimally Treated Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph-ALL)
Inotuzumab Ozogamicin (IO; CMC544), a CD22 Monoclonal Antibody Attached to Calicheamycin, Produces Complete Response (CR) plus Complete Marrow Response.
Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results.
Ibrutinib in Combination with Rituximab (iR) Is Well Tolerated and Induces a High Rate of Durable Remissions in Patients with High- Risk Chronic Lymphocytic.
Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) versus Bendamustine and Rituximab (BR) in Previously Untreated and.
Phase II Trial of R-CHOP plus Bortezomib Induction Therapy Followed by Bortezomib Maintenance for Previously Untreated Mantle Cell Lymphoma: SWOG 0601.
Brentuximab Vedotin in Combination with RCHOP as Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study Yasenchak CA et al. Proc.
Daunorubicin VS Mitoxantrone VS Idarubicin As Induction and Consolidation Chemotherapy for Adults with Acute Myeloid Leukemia : The EORTC and GIMEMA Groups.
J Clin Oncol August Vol 28 R2. 석화영 / Pf. 윤휘중.
Kantarjian HM et al. Proc ASH 2012;Abstract Long-Term Follow-Up of Ongoing Patients in 2 Studies of Omacetaxine Mepesuccinate for Chronic Myeloid.
Preliminary Results of a Multicenter Phase II Trial of 5-Day Decitabine as Front-Line Therapy for Elderly Patients with Acute Myeloid Leukemia (AML) Cashen.
ELIANA: CTL019 Shows High CR Rate in Pediatric/Young Adult Patients With Relapsed/Refractory B-Cell ALL New Findings in Hematology: Independent Conference.
For public (redacted) Blinatumomab for previously treated B-precursor acute lymphoblastic leukaemia [ID804] 1st Appraisal Committee meeting Background.
Summary Author: Dr. C. Tom Kouroukis, MD MSc FRCPC
Geisler C et al. Proc ASH 2011;Abstract 290.
Vadastuximab Talirine + Hypomethylating Agents Active and Well Tolerated in Untreated Older Patients With AML New Findings in Hematology: Independent Conference.
39th ESMO Congress Madrid, Spain – 30 September Poster 979P
Chen R et al. Proc ASH 2015;Abstract 518.
New Findings in Hematology: Independent Conference Coverage
19-28z CAR T-Cell Efficacy and Toxicity in Adults With R/R B-Cell ALL
Addition of Vadastuximab Talirine to Induction Therapy for Newly Diagnosed AML: Phase Ib Dose-Escalation Trial New Findings in Hematology: Independent.
Final Results from a Phase 2 Study of Pracinostat in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML)1   CC-486 (Oral.
1 Stone RM et al. Proc ASH 2015;Abstract 6.
NCI 9177: Risk-Adapted DA-EPOCH-R in Adults With Burkitt Lymphoma
Palumbo A et al. Proc ASH 2012;Abstract 200.
Maury S et al. Proc ASH 2015;Abstract 1.
This activity is supported by an educational grant from Shire.
Blinatumomab After AlloHSCT in Patients With R/R B-Precursor ALL
Attal M et al. Proc ASH 2010;Abstract 310.
Korde N et al. Proc ASH 2012;Abstract 732.
CCO Independent Conference Highlights
Nivolumab in Patients (Pts) with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Clinical Outcomes from Extended Follow-up of a Phase 1 Study.
DiNardo C et al. Proc ASH 2015;Abstract 327.
Platzbecker U et al. Proc ASH 2014;Abstract 12.
IFM/DFCI 2009 Trial: Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM) in the Era of New Drugs Phase III study of lenalidomide/bortezomib/dexamethasone.
RATIFY: Midostaurin Added to Standard Chemotherapy Prolongs OS in Patients With Newly Diagnosed FLT3-Mutated AML New Findings in Hematology: Independent.
Slide set on: McCarthy PL, Owzar K, Hofmeister CC, et al
Oki Y et al. Proc ASH 2013;Abstract 252.
CALGB/Alliance 50303: R-CHOP vs DA-EPOCH-R in Newly Diagnosed Diffuse Large B-Cell Lymphoma New Findings in Hematology: Independent Conference Coverage.
ASCO Recap Palak Desai, MD.
New Findings in Hematology: Independent Conference Coverage
Martinelli G et al. Proc ASH 2015;Abstract 679.
Jabbour E et al. Proc ASH 2015;Abstract 83.
San Miguel JF et al. 1 Proc EHA 2013;Abstract S1151.
Goede V et al. Proc ASH 2014;Abstract 3327.
New Findings in Hematology: Independent Conference Coverage
WHAT IS THE BEST Front-Line REGIMEN for Patients With CLL
Erba HP et al. Blood 2008;112: Abstract 558
Anthracycline Dose Intensification in Acute Myeloid Leukemia
Ferrajoli A et al. Proc ASH 2010;Abstract 1395.
Niesvizky R et al. Proc ASH 2010;Abstract 619.
Jonathan W. Friedberg M.D., M.M.Sc.
Vitolo U et al. Proc ASH 2011;Abstract 777.
Faderl S et al. Proc ASCO 2011;Abstract 6503.
What is the best frontline regimen for CLL patients
Seymour JF et al. Proc ASH 2013;Abstract 872.
Zaja F et al. Proc ASH 2010;Abstract 966.
Blinatumomab Versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
1 Verstovsek S et al. Proc ASH 2012;Abstract Cervantes F et al.
Ahmadi T et al. Proc ASH 2011;Abstract 266.
Advani RH et al. Proc ASH 2011;Abstract 443.
Presentation transcript:

Acute Lymphoblastic Leukemia ⎼ Posters and Abstracts from San Diego 60th ASH Annual Meeting & Exposition

Blinatumomab for Minimal Residual Disease in Adults with B-Cell Precursor Acute Lymphoblastic Leukemia BLAST Study Follow-Up Gökbuget N, et al. ASH 2018. Abstr 554.

BLAST Study Design1 and Follow-Up2 Open-label, single-arm phase 2 study Pts (N=116, age ≥18 years with BCP-ALL in first or later hematologic CR and with persistent or recurrent MRD≥10-3 after a minimum of 3 cycles of intensive chemotherapy) received blinatumomab 15 μg/m2/d by continuous IV infusion for up to 4 cycles (each cycle: 4 weeks of blinatumomab infusion → 2 weeks, treatment-free). MRD evaluation: real-time qPCR performed mostly in the central reference laboratory or in national reference laboratories. The primary endpoint: the rate of complete MRD response after blinatumomab cycle 1 The current update (minimum F/U = 3 years; median F/U = 53.1 months after blinatumomab treatment) reports long-term OS in 110 pts with Ph- BCP-ALL and <5% blasts at enrollment, including 74 who received allo-SCT while in continuous CR after blinatumomab treatment. 1. Gökbuget N, et al. Blood. 2018;131:1522-1531. 2. Gökbuget N, et al. ASH 2018. Abstr 554.

BLAST Study Follow-Up Overall Survival Median OS = 36.5 months (reached a plateau) Complete MRD responders (n=85) = NR (95% CI: 27.3 months to NR) Underwent allo-SCT in continuous CR (n=61) = NR (95% CI: 25.7 months to NR) MRD+ in CR1 (n=60) = NR (95% CI: 29.5 months to NR) MRD non-responders (n=22) = 12.5 months (95% CI: 3.2 to 39.7) Underwent allo-SCT in continuous CR (n=10) = 16.1 months (95% CI: (1.1 to NR) MRD+ in CR1 (n=13) = 10.6 months (95% CI: 2.7 to 39.7) Gökbuget N, et al. ASH 2018. Abstr 554.

BLAST Study Follow-Up Summary and Faculty Takeaways This update further demonstrates the long-term OS benefits of blinatumomab treatment in adults with MRD+ BCP-ALL. The MRD+ is a sign of disease refractoriness, not just a biomarker, and pts who are MRD+ have a very poor outcome. We should not transplant pts while they are MRD+, we should make every effort to attain MRD- status, and blinatumomab is highly effective in this regard. In practice, check for MRD+, whether due to a persistent disease or relapse, give them blinatumomab and, then, if MRD-, go for transplant. Down the road, the role of transplant may become questionable; do we go for transplant or not? I would say, today, yes, but in the future, things may change. Gökbuget N, et al. ASH 2018. Abstr 554.

Inotuzumab Ozogamicin + Mini-Hyper-CVD ± Blinatumomab in Newly Diagnosed Older Patients With Ph- ALL Phase II Study Short NJ, et al. ASH 2018. Abstr 36.

INO + Mini-Hyper-CVD ± Blinatumomab Phase II Study Design Pts (N=58), median age 68 years (required to have a PS of ≤3, total bilirubin ≤1.5 mg/dl, AST/ALT ≤3x ULN and creatinine ≤2 mg/dl), with newly diagnosed Ph- pre-B ALL received mini-hyper-CVD for up to 8 cycles. INO given at a dose of 1.3-1.8mg/m2 on day 3 of cycle 1, and 0.8-1.3mg/m2 on day 3 of cycles 2-4. Pts 1-6 received 1.3 mg/m2 for cycle 1 followed by 0.8 mg/m2 for subsequent cycles, while pts 7+ received the phase II dose of 1.8 mg/m2 for cycle 1 followed by 1.3 mg/m2 for subsequent cycles. Rituximab (if CD20+) and prophylactic IT chemotherapy were given for the first 4 cycles. Responding pts received POMP maintenance for up to 3 years. Short NJ, et al. ASH 2018. Abstr 36.

INO + Mini-Hyper-CVD ± Blinatumomab Phase II Study Protocol Amendment After the observation of VOD, the protocol was amended in 9/2015 to use lower doses of INO. Pts (35+) received INO at 1.3 mg/m2 in cycle 1, and 1 mg/m2 in all of the subsequent cycles. Another amendment was made in 3/2017 (pts 50+) to give INO in split doses each cycle (0.6 mg/m2 on day 2, and 0.3 mg/m2 on day 8 of cycle 1; 0.3 mg/m2 on day 2, and 8 of cycles 2-4) and 4 cycles of blinatumomab at standard dosing after the INO-based cycles, for a total of 4 cycles, and before the initiation of the maintenance therapy (i.e. cycles 5-8). Short NJ, et al. ASH 2018. Abstr 36.

INO + Mini-Hyper-CVD ± Blinatumomab Key Findings ORR = 98% (CR = 87%) 3-year OS = 54% MRD- status by 6-color flow cytometry was achieved in 39/52 pts (75%) after 1 cycle and 54/57 pts (95%) overall. There were no early deaths, and the 30-day and 60-day mortality rates were 0% and 3%, respectively. 54% of pts remain on treatment. Short NJ, et al. ASH 2018. Abstr 36.

INO + Mini-Hyper-CVD ± Blinatumomab Summary and Faculty Takeaways Mini-hyper-CVD + INO ± blinatumomab proved to be safe and effective in elderly pts with newly diagnosed Ph- ALL. Compared to a similar historical cohort of older pts treated with hyper-CVAD ± rituximab, mini-hyper-CVD + INO ± blinatumomab resulted in significantly higher 3-year OS. This regimen is likely to set the stage for a new standard of care for elderly pts with newly diagnosed Ph- ALL. Short NJ, et al. ASH 2018. Abstr 36.

Sequential Mini-Hyper-CVD + Inotuzumab Ozogamicin ± Blinatumomab in Patients With R/R Ph- ALL Phase II Study Sasaki K, et al. ASH 2018. Abstr 553.

Mini-Hyper-CVD + INO ± Blinatumomab Phase II Study Design The mini-hyper-CVD (cycles 1, 3, 5, 7) included cyclophosphamide (150 mg/m2 every 12 h on days 1-3), vincristine (2 mg on days 1 and 8), and dexamethasone (20 mg on days 1-4 and 11-14) without doxorubicin; cycles 2, 4, 6, 8 included methotrexate (250 mg/m2 on day 1) and cytarabine (0.5 g/m2 given every 12 h on days 2 and 3). INO was originally given on day 3 of the first 4 cycles at the dose of 1.3-1.8 mg/m2 at cycle 1, followed by 1.0-1.3 mg/m2 in subsequent cycles. Rituximab and IT chemotherapy were given for first 4 courses. Sasaki K, et al. ASH 2018. Abstr 553.

Mini-Hyper-CVD + INO ± Blinatumomab Phase II Study Protocol Amendment After 67 pts were treated protocol was amended to incorporate 4 cycles of blinatumomab after 4 cycles of mini-hyper-CVD + INO, which was given on days 2 and 8 at the dose of 0.6 and 0.3 mg/m2 in cycle 1, respectively, and on days 2 and 8 of subsequent cycles at the dose of 0.3 mg/m2. Blinatumomab was infused over 28 days every 42-day cycle for 4 cycles. Sasaki K, et al. ASH 2018. Abstr 553.

Mini-Hyper-CVD + INO ± Blinatumomab Key Findings From 2/2013 to 5/2018, 84 pts (median age = 35 years; 23% of pts had prior allo-SCT) were enrolled and treated, including 17 pts with mini-hyper-CVD + INO + blinatumomab. The median follow-up was 31 months. ORR = 80% (CR = 58%) Median OS = 25, 6, and 7 months in salvage 1, 2, and 3 or more, respectively MRD- status by 6-color flow cytometry was achieved in 51/64 pts (80%); 85% in salvage 1. The VOD incidence was reduced from 9/61 (15%) with single dose of INO to 0/18 (0%) with weekly divided dose schedule. Sasaki K, et al. ASH 2018. Abstr 553.

Mini-Hyper-CVD + INO ± Blinatumomab Summary and Faculty Takeaways The combination of mini-hyper-CVD and INO ± blinatumomab is effective and shows encouraging results in patients with R/R Ph- ALL. Historical comparison showed median OS of 14 months and 6 months in hyper-CVD + INO ± blinatumomab and INO as a single agent, respectively. The VOD risk can be reduced with fractionated INO dosing. This represents a new standard of care for pts with R/R Ph- ALL. Sasaki K, et al. ASH 2018. Abstr 553.

Sequential Hyper-CVAD With Blinatumomab as Frontline Therapy for Adults With Ph- B-Cell ALL Phase II Study Richard-Carpentier G, et al. ASH 2018. Abstr 32.

Sequential Hyper-CVD + Blinatumomab Phase II Study Design Pts (N=19; median age 42 years) had newly diagnosed untreated (or were in CR after one prior course of hyper-CVAD; n=3) Ph- B-ALL or B-cell lymphoblastic lymphoma, ECOG PS of 0-3, with normal liver, kidney, and cardiac function. Therapeutic regimen: 4 alternating cycles of Hyper-CVAD → 4 consecutive cycles of blinatumomab (4 weeks every 6 week-cycle) All pts received 8 prophylactic IT injections with methotrexate and cytarabine during the first 4 cycles of treatment. Pts with CD20+ ALL (≥1% cells) received a total of 8 doses of rituximab (375 mg/m2) or ofatumumab (2000 mg) during the hyper-CVAD cycles. Maintenance: POMP (cycles 1-3, 5-7, 9-11 and 13-15) alternating with blinatumomab (cycles 4, 8 and 12) Richard-Carpentier G, et al. ASH 2018. Abstr 32.

Sequential Hyper-CVD + Blinatumomab Key Findings ORR = 100% (CR = 100%) 1-year OS = 93% MRD- status by 6-color flow cytometry was achieved in 93% of the pts after 1 cycle of therapy. The treatment was well tolerated. One patient developed transient Grade 3 CRS and 1 had Grade 3 ataxia; both recovered after holding blinatumomab therapy and dexamethasone administration; thereafter, treatment was resumed with no AE recurrence. With a median follow up of 17 months, 18 pts (95%) are alive. Richard-Carpentier G, et al. ASH 2018. Abstr 32.

Sequential Hyper-CVD + Blinatumomab Summary and Faculty Takeaways The sequential combination of Hyper-CVAD and blinatumomab in newly diagnosed adult patients with B-ALL is safe and highly effective. Of note, most of the pts had bad features such as t(4;11), CRLF2+, TP53 mutations, and others. This study is still accruing pts. Eventual positive outcomes may mean that in the future we can get rid of the intensive chemotherapy. Richard-Carpentier G, et al. ASH 2018. Abstr 32.

Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Ph- B-Cell ALL Phase II SWOG 1318 Trial Advani AS, et al. ASH 2018. Abstr 33.

Blinatumomab → POMP Maintenance Phase II SWOG 1318 Trial Design Pts (N=29; median age 75 years) received blinatumomab for induction (standard dose for 1-2 cycles) until CR/CRi → 3 cycles of blinatumomab post-remission therapy → 18 months of maintenance POMP. A total of 8 doses of IT methotrexate were administered as CNS prophylaxis. Response was assessed at the completion of 1-2 cycles of blinatumomab. The primary objective of the study was to estimate 3-year OS. Advani AS, et al. ASH 2018. Abstr 33.

Phase II SWOG 1318 Trial Key Findings ORR = 66% (CR = 100%) 1-year OS = 67% 1-year DFS = 58% MRD- status by 8-color flow cytometry was achieved in 92% of the pts after 1 cycle of therapy. The treatment was well tolerated. Grade 3 CRS (n=1) and Grade 3 neurotoxicity (n=1) were reported. Advani AS, et al. ASH 2018. Abstr 33.

Phase II SWOG 1318 Trial Summary and Faculty Takeaways Blinatumomab was well tolerated and effective in the treatment of newly diagnosed elderly patients with Ph- B-cell ALL. Further follow-up will ascertain the durability of these responses. Advani AS, et al. ASH 2018. Abstr 33.

Subgroup Analysis of HRQoL Blinatumomab vs SOC Chemotherapy in Patients With R/R Ph- ALL TOWER Trial Stein AS , et al. ASH 2018. Abstr 3967.

Adults with heavily pre-treated Ph- BCP-ALL TOWER Trial Design Blinatumomab (n=271) Induction, if ≤5% bone marrow blasts → consolidation Week 1: 9 μg/d; weeks 2-4: 28 μg/d; weeks 5 & 6: no therapy If ≤5% bone marrow blasts → maintenance Four-week continuous infusion every 12 weeks Adults with heavily pre-treated Ph- BCP-ALL (N=405) Randomization 2 : 1 (blinatumomab : SOC) SOC Chemotherapy (n=134) Induction, if ≤5% bone marrow blasts → consolidation If ≤5% bone marrow blasts → maintenance The primary endpoint: OS Secondary end points: CR, CR duration, EFS, MRD, AEs Chemotherapy: fludarabine, high-dose cytarabine, and granulocyte colony-stimulating factor +/- anthracycline; high-dose cytarabine-based regimen; a high-dose methotrexate-based regimen; clofarabine-based regimen. Kantarjian H, et al. N Engl J Med. 2017;376:836-847.

TOWER Trial: HRQoL Subgroup Analysis Key Findings HRQoL was assessed using the EORTC QLQ-C30 Questionnaire on days 1 (baseline), 8, and 15; on day 29 of cycle 1; days 1, 15, and 29 of consolidation; and at the safety follow-up. The questionnaire included 1 global health status scale, 5 functioning scales, 3 symptom scales, and 6 single-symptom items. In total, 342 pts (blinatumomab, n=247; SOC, n=95) had ≥1 HRQoL result: low blasts, n=87 (blinatumomab, n=64; SOC, n=23); high blasts, n=255 (blinatumomab, n=183; SOC, n=72) Global health status was improved by blinatumomab regardless of baseline blast level; however, this improvement was somewhat greater in the low blasts group. When the function scores worsened, the extent of worsening was almost always smaller for blinatumomab vs SOC, particularly in the high blasts group. Functioning status scores tended to stay the same or worsen with both blinatumomab and SOC regardless of blast level, except emotional scores, which improved with blinatumomab regardless of blast level. Generally, symptom scores improved with blinatumomab but not with SOC, particularly in patients with high blasts. Stein AS , et al. ASH 2018. Abstr 3967.

TOWER Trial: HRQoL Subgroup Analysis Summary and Faculty Takeaways Blinatumomab improved HRQoL in pts with R/R Ph- BCP-ALL and delayed the time to clinically meaningful deterioration in HRQoL vs SOC. The difference between blinatumomab and SOC with regard to HRQoL was greater among pts with high disease burden. Of note, blinatumomab does improve the functioning of the pts, not only their survival and their response rates. Stein AS , et al. ASH 2018. Abstr 3967.

Abbreviations (1 of 2) AEs: adverse events ALL: acute lymphoblastic leukemia allo-SCT: allogeneic stem-cell transplantation AST/ALT: aspartate transaminase/alanine transaminase BCP: B-cell precursor CR: complete remission CRi: CR with incomplete count recovery CRS: cytokine release syndrome DFS: disease-free survival ECOG PS: Eastern Cooperative Oncology Group Performance Status EFS: event-free survival F/U: follow-up HRQoL: health-related quality of life Hyper-CVAD: hyper-fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate/cytarabine every 21 days INO: inotuzumab ozogamicin

Abbreviations (2 of 2) IT: intrathecal IV: intravenous MRD: minimal/measurable residual disease Mini-hyper-CVD: cyclophosphamide and dexamethasone at 50% dose reduction, no doxorubicin, methotrexate at 75% dose reduction, and cytarabine at 0.5 g/m2 × 4 doses NR: not reached ORR: overall response rate OS: overall survival Ph: Philadelphia chromosome POMP: 6‐mercaptopurine, vincristine, methotrexate, and prednisone qPCR: quantitative polymerase chain reaction R/R: relapsed/refractory SOC: standard of care TKI: tyrosine kinase inhibitor ULN: upper limit of normal VOD: veno-occlusive disease